UPMC | HILLMAN CANCER CENTER

Antineoplastic Therapy and Immunotherapy Course

This four-day course is designed to address the needs of the nursing and other oncology professionals in relation to antineoplastic and immunotherapies. It includes information on current and investigational pharmacotherapy, safe handling, administration of antineoplastic agents, and various issues concerning the management of patients receiving cancer therapy.

This course is NOT a certification course and is not intended to measure competency. Individual institutions are responsible for determining their own requirements for assessing clinical competency. It is strongly recommended that attendees have taken the Foundations to Practice series prior to completing this course.

All courses are sponsored by UPMC Hillman Cancer Center. The faculty consists of healthcare professionals with expertise in cancer care at UPMC.

Time and Location:
This course will be held virtually via Microsoft Teams. Exact class schedule will be provided in the confirmation letter sent via e-mail one week prior to the class. Electronic registration begins at 7:45 a.m. and lectures begin promptly at 8:00 a.m. The course concludes at approximately 4:00 p.m.

Who Should Attend:
The course is designed for nurses and other oncology professionals involved in cancer care. Six months of oncology experience and the completion of the Foundations to Practice Series (Pathophysiology of Cancer, Cancer Treatment Modalities, and the Immune System; Overview of Solid Tumors; Symptom Management of Patients with Cancer; Oncology Emergencies and Advanced Cancer Care Issues; and Hematological Malignancies) or other introductory cancer courses are *strongly recommended*.

Continuing Education Credit:
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 25.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

The maximum number of hours awarded for this Continuing Nursing Education activity is 25.5 contact hours.

To receive 25.5 Contact Hours, the learner must sign into each class day via Microsoft Teams, attend all four class days, and pass the exam with an 80% or greater. Following test completion, the learner will complete the evaluation on the CCE site and claim credit.

This certificate confirms that the participant has successfully completed the course and has the theoretical foundation needed to administer antineoplastic therapy and immunotherapy agents. This is not a certification course; individual institutions are responsible for determining their own requirements based on internal policies for assessing clinical competency in chemotherapy and immunotherapy administration.

Registration Information:
All UPMC employees are required to register for educational programs through Learning via HR Direct. A User Guide is available on the Infonet. Manager approval may be required for some programs for some employees. If you receive this notice when enrolling, please notify your manager of your interest in the program.

Non-UPMC employees may register for the course by submitting a course registration form to the course director. Registration forms are located on the UPMC Hillman Cancer Center Professional Education Website https://hillman.upmc.com/health-care-professionals/education/courses

The registration fee for this course for virtual attendance is $150. The registration fee includes program materials. Tuition is waived for employees of UPMC and UPMC affiliates. Deadline for registration is one week before the course date.

Confirmation letters are emailed to all registrants one week prior to class and contain an activity information sheet (agenda), course homework, slide decks, study guide, and workbook, registration link for CE credit, as well as other details.

If you have any questions, need more information, or do not receive confirmation prior to the course, contact Maura Miller at kimballmk2@upmc.edu

Cancellation Policy:
- If you cannot attend any course day for any reason, you need to directly notify the course registrar, Maura Miller, by emailing kimballmk2@upmc.edu
- The course schedule is not changed by school delays.
- For class cancellations, an announcement via email will be sent to class attendees.

The program sponsors reserve the right to make changes or cancel the program because of unforeseen circumstances.

Personal Accommodations:
Please indicate any personal accommodations you may need for the program, such as sign language interpreter, large print conference materials, braille conference materials, wheelchair height tables, accessible parking, or other. Please email kimballmk2@upmc.edu two weeks prior to the program if you need any personal accommodations to participate.

Antineoplastic Therapy and Immunotherapy Course

Course Objectives

Upon completion of this course, participants will be able to:

- Compare and contrast the mechanism of action between antineoplastic therapy and immunotherapy.
- Recall the side effect profiles for the different classes of antineoplastic agents and immunotherapies.
- Recall nursing care considerations for patients receiving antineoplastic therapy and immunotherapy.
- Compare and contrast the mechanisms of action, side effect profile, complications, and management of side effects for patients receiving novel treatment modalities including Car T-cell therapy, BiTE therapy, and TIL cell therapy.
- Describe the role that chemotherapy protectants play in the treatment of cancer.
- Recall patient barriers to adherence of oral cancer medications.
- Apply principles of antineoplastic therapy drug administration in calculating drug doses to include calculation of body surface area (BSA), absolute neutrophil count (ANC), creatinine clearance (Cr Cl) and carboplatin dosing.
- Describe the steps to ensure safe administration of antineoplastic and immunotherapy agents.
- Identify assessment priorities to effectively manage patient symptoms, dose-limiting toxicities, and adverse effects of antineoplastic therapy and immunotherapy.
- Recognize relevant resources for proper use of personal protective equipment (PPE) and excretion precautions.
- Prioritize the appropriate interventions for the management of hypersensitivity reactions.
- Describe the appropriate interventions for the management of vesicant extravasation.
- Discuss the differences between cancer genetics and cancer genomics.
- Identify the role that growth factors play when treating oncology patients.
- Recall strategies to prevent medication errors.

Course Content

- Alkylating Agents
- Antimetabolites
- Antineoplastic Therapy Administration
- Antitumor Antibiotics
- BiTE Therapy
- CAR T- Cell Therapy
- Case Study and Comprehensive Review
- Check Point Inhibitors
- Chemotherapy Protectants
- Error Prevention
- Extravasation
- Genetics and Genomics
- Growth Factors
- Hormonal Therapies
- Hypersensitivity Reactions

- Interferon, Interleukin, L-Asparaginase, and Vaccine Therapy
- Miscellaneous Agents
- Monoclonal Antibodies
- Plant Alkaloids
- Principles of Cancer Drug Therapy
- Professional Resources
- Oral Adherence
- Organ Toxicities
- TIL Therapy
- Tyrosine Kinase Inhibitors